Loading company…
Neuromodtronic develops Eyetronic, a non-invasive therapy for visual field loss linked to glaucoma and optic nerve disorders.
Founded in 2007 and based in Potsdam, Germany, Neuromodtronic develops Eyetronic Therapy, which uses patient-specific alternating current to stimulate surviving retinal nerve cells. The therapy has been available at select medical centers since 2014. In June 2017, the company raised EUR 3 mn in venture debt funding from Hayfin Capital Management to support growth, expansion in EU countries, and a US clinical trial.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in